Small Molecule-Drug Conjugates: Getting Small to Enhance Targeting

Time: 8:40 am
day: Day Two


  • While the clinical benefit of ADCs has become evident, the therapeutic window of these biopharmaceuticals is narrower than what had initially been estimated on the basis of preclinical studies
  • The chemical conjugation of a small organic tumour targeting moiety to a cytotoxic drug leads to the generation of a novel class of therapeutic compounds named small molecule-drug conjugates (SMDCs)
  • We present preclinical and clinical results obtained with small ligands targeting two promising tumour-associated antigens overexpressed in solid tumours: CAIX and FAP